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We have shown earlier that certain proline-directed kinases such as MAP kinase or GSK3 can phosphorylate tau protein in an abnormal manner 
reminiscent of tau from Alzheimer paired helical filaments [Drewes et al. (1992); Mandelkow et al. (199211. Both kinases are abundant in brain 
tissue and associate physically with microtubules through several cycles of assembly and disassembly. In this report we show that cdk2/cyclinA 
incorporates =5 Pi into recombinant au, and that it also induces the Ma shift and antibody reactivity typical of Alzheimer tau. However, since 
there is no cdk2 in brain [Meyerson et al. (1992)] we looked for other members of this family of kinases. Using an antibody against he conserved 
N-terminus we isolated a cdk-like kinase from brain which was capable of inducing the Alzheimer-like characteristics in tau by phosphorylation. 
Its size (31 kDa), target specificity (proline-directed), chromatographic behavior, and abundance in brain suggest hat this kinase is similar or 
identical to the neuronal cdc2-like kinase nclk alias PSSARLE or cdk5 [Hellmich et al. (1992); Meyerson et al. (1992); Xiong et al. (1992); Tsai 
et al. (1993)]. This was confirmed by an antibody specific for cdk5. Like MAP kinase and GSK3, this kinase is physically associated with 
microtubules and can be enriched by cycles of microtubule assembly and disassembly. Thus, cdk5 should be regarded as another kinase that could 
be held responsible for the changes in tau protein during Alzheimer disease progression. 
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1. INTRODUCTION 
Tau protein, a microtubule-associated protein, is the 
main component of the pathological paired helical fila- 
ments (PHFs) found in the brains of Alzheimer patients. 
PHF tau, in contrast to normal tau, is anomalously 
phosphorylated, suggesting that phosphorylation de- 
fects may be involved in Alzheimer’s disease (for review, 
see [19,23,50]). Our previous studies on tau phosphoryl- 
ation have yielded the following results. (a) A kinase 
activity can be prepared from normal or Alzheimer 
brains which phosphorylates mostly SP or TP motifs in 
the presence of the phosphatase inhibitors okadaic acid 
(for PP-2A) and EGTA (for calcineurin) [l 11. (b) An 
‘Alzheimer-like’ state of tau protein can be defined by 
antibodies which discriminate between normal and 
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PHF tau and which react with SP motifs in a phospho- 
rylation-dependent manner [2,25]. (c) Phosphorylation 
at SP and TP motifs of tau can be achieved by the 
proline-directed kinases MAP kinase or GSK-3 [8,26]; 
these kinases also induce the ‘Alzheimer-like’ antibody 
reactivity. These results were broadly in agreement with 
those of several other groups pointing to the importance 
of proline-directed kinases acting on tau (e.g. [12,15- 
17,21,33,35,45]). 
These data suggested that MAPK or GSK-3 might be 
involved in the dysregulation of tau’s phosphorylation, 
but they did not exclude the possiblity that other kinases 
might be equally important. In our experiments the cell 
cycle kinase cdcucyclin A or B (also a proline-directed 
kinase) phosphorylated tau only with low efficiency [8], 
but one could argue that the negative results on cdc2 
might not be very meaningful since this kinase regulates 
the entry into mitosis which does not occur in differen- 
tiated neurons. In this report we describe the ability of 
other cyclin dependent kinases (cdk’s) to phosphorylate 
tau. We notice that cdk2/cyclin A, a kinase regulating 
the Gl and S phases in vertebrate cells [41], was able to 
evoke the Alzheimer-like antibody reactivity. However, 
this kinase is present in many tissues but not in brain 
[28] and therefore seemed unlikely to affect tau in vivo. 
This prompted us to look for cdcZlike kinases in brain 
that would also phosphorylate tau in an abnormal fash- 
ion. This resulted in the isolation of a kinase of 
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M, = 31 kDa which induces the Alzheimer-like state 
very efficiently when complexed to a 25 kDa cofactor, 
and in addition is bound to microtubules and Alzheimer 
PHFs, making it a particularly interesting kinase for 
studying the pathological phosphorylation of tau. Judg- 
ing by biochemical properties this kinase is similar if not 
identical to nclk, alias PSSALRE or cdk5, a relative of 
cdd which is abundant in brain [14,24,28,37,42,49]. 
2. MATERIALS AND METHODS 
The methods used here have been described in recent publications 
so that only some key points will be repeated. Recombinant human 
tau proteins were derived from the cDNA clones of Goedert et al. [9] 
and expressed in E. coli [2], using derivatives of the PET expression 
vector [40]. Point mutants were made by PCR. Phosphorylation by the 
brain kinase activity was done following Gustke et al. [l 11. Fig. IA 
shows a diagram of the domain structure of htau40 and its main 
phosphorylation sites. 
Antibodies against tau were obtained from Dr. L. Binder (TAUl, 
[4]), Innogenetics S.A., Ghent, Belgium; (AT8 [271), and Sternberger 
Monoclonals Inc., Baltimore, MD (SMI 31,33,34; Stembcrger et al. 
[39]). We had previously determined their epitopes [2,25]. TAUl and 
SM133 react with normal (or recombinant unphosphorylated) tau, 
ATS, SM131 and SM134 react with Alzheimer PHFs, or with tau 
phosphorylated by MAP kinase or the brain extract (Fig. 1A). An 
antibody against the conserved N-terminal region of cdc2 was ob- 
tained from UBI (Lake Placid, NY). The antibody against cdk5 was 
provided by Dr. L.-H. Tsai (MGH Cancer Center). 
2.1. Purification of 31 kDa kinase 
Fresh porcine brains obtained from the local slaughter house were 
cleaned from meninges and blood vessels. 500 g of tissue was homog- 
enized at 4°C in 500 ml of buffer containing 25 mM Tris-HCl, pH 7.4, 
50 mM NaCl, 20 mM NaF, 2 mM EGTA, 2 mM DTT, 2 mM MgCl,, 
0.2 mM Na,VO,, 0.1% Nonidet P 40,2 mM MgATP, 2 mM benzamid- 
ine, 0.5 mM PMSF, 2 &ml leupeptin, pepstatin and aprotinin and 
centrifuged at 100,000 x g for 60 min. The supematant was pooled and 
clarified by another centrifugation step and then applied onto a 
Q-Sepharose column (200 ml, Pharmacia) equilibrated with buffer A 
(50 mM Tris-HCI, pH 8.0, containing 2 mM EGTA, 0.5 mM DTT, 
3 mM MgCl,, 0.2 mM NajV04, 0.1% Nonidet P40, 2 mM MgATP, 
1 mM benzamidine,, 0.5 mM PMSF, 2 &ml leupeptin, pepstatin and 
aprotinin). The pH of the flow-through fraction was adjusted to 6.5 
with 0.5 M MES and then applied onto a S-Sepharose column (50 ml, 
Pharmacia) equilibrated with buffer B (25 mM MES-NaOH, pH 6.0, 
containing 2 mM EGTA, 0.5 mM DTT, 3 mM MgC&, 0.2 mM 
Na,VO,, 0.1% Nonidet P40, 2 mM MgATP, 1 mM benzamidine, 0.5 
mM PMSF, 2 &nI leupeptin, pepstatin and aprotinin). Bound pro- 
tein was eluted with a gradient of &500 mM NaCl in buffer B at a 
flow rate of 5 ml/min in 100 min. The fractions (25 ml) were assayed 
by Western blotting with anti-&2 or anti-cdk5 antibody. Active frac- 
tions were pooled and dialysed against buffer B (pH 6.5) and then 
loaded on a SP-Sepharose HP column (10 ml; Pharmacia) equilibrated 
with the same buffer. Elution was performed stepwise with O-500 mM 
NaCl (each step 25 mM for 2.5 min) at a flow rate of 4 ml/mm. 
Anti-c&2 (or anti-cdk5) positive fractions (10 ml) were pooled, dialy- 
sed against buffer A (PH 8.4) and then applied onto a Mono-Q HR 
lo/IO FPLC column (Pharmacia) equilibrated with the same buffer. 
Elution was carried out with a linear gradient from O-500 mM NaCl 
at a flow rate of 2 ml/min over 80 min. Anti-&2 or -cdk5 positive 
fractions were pooled and dialysed against buffer A (pH 8.25). This 
pool was loaded on a Mono-Q HR 5/5 (Pharmacia) equilibrated with 
buffer A (pH 8.25) and bound protein was elutcd with a stepwise 
gradient from &300 mM NaCl (each step 30 mM for 2 mitt) in the 
same buffer over 20 min at a flow rate of 0.5 ml/mm. 
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Fractions (1 ml) positive on Western blots were assayed for their 
phosphorylation activity of tau protein or p34 substrate peptide (SV 
40 T antigen peptide, Gibco BRL). Active fractions were submitted 
to gel filtration on a G200 Superdex HR 16/60 column (Pharmacia) 
equilibrated with buffer A @H 7.4) containing 150 mM NaCl and 
eluted with the same buffer at a flow rate of 0.3 ml/min. Fractions 
(2 ml) were assayed for their phosphorylation activity of p34 substrate 
peptide and active fractions were pooled and dialysed against buffer 
A (pH 8.25) followed by ion exchange chromatography on a Mono-Q 
1.616 Smart column (Pharmacia) equilibrated with the same buffer. 
Bound protein was eluted with gradient from O-300 mM NaCl in the 
same buffer over 20 min at a flow rate of 0.1 ml/min. Active and 
anti-cdk5 positive fractions (0.1 ml) were pooled and quickly desalted 
on a PD 3X0 column (Pharmacia) equilibrated with buffer B (pH 
6.5) and then applied onto a Mono-S 1.6/6 Smart column (Pharmacia). 
Elution was performed with a gradient of 50-250 mM NaCl in buffer 
B @H 6.5) over 10 min and 0.1 ml fractions were collected. All steps 
were carried out at 4°C. The purified protein fractions were checked 
at each step with antibodies against MAP kinase and GSK3 to ascer- 
tain that these kinases were no longer present. Phosphorylation assays 
were performed after each chromatography step. 
Purification of cdk2/cyclin A (GST fusion protein) from baculovirus 
transfected St9 insect cells was done by precipitation with glutathione- 
agarose beads, as described elsewhere 1311. 
2.2. Phosphorylation of tau 
0.4 ,ul of kinase fractions were added to aliquots of a solution of 
htau34 or other tau constructs (0.2 mg/ml) in 40 mM HEPES, pH 7.4, 
containing 2 mM [y-‘*P]ATP (25-50 Ci/mol), 3 mM MgCl,, 5 mM 
EGTA, 2 mM DTT, 0.5 mM PMSF, to a final folume of 4 ~1. After 
incubation at 37°C for different time intervals, the reaction was stop- 
pen by addition of SDS-PAGE sample buffer. After electrophoresis 
on 7-158 gradient gels and staining with Coomassie blue, tau bands 
were excised and the incorporated radioactivity was determined by 
Cerenkov counting. 
2.3. Phosphorylation of p34 substrate peptide 
0.5 ~1 of kinase fractions were added to ahquots of a solution of the 
substrate peptide (0.5 mM) in 50 mM Tris-HCl, pH 7.4 containing 0.1 
mM [y-‘*P]ATP (1 Cilmmol), 2 mM MgCl,, 1 mM DTT, 5 mM 
EGTA, 0.5 mM PMSF to a final volume of 5 ~1. After incubation at 
37°C for 30 min, the reaction was stopped by addition of an equal 
volume of 20% TCA. Samples were centrifuged for 5 min at 14,000 x g 
to remove protein. 8 ~1 of the supematant was spotted on P81 cellulose 
paper disks (Gibco BRL) and washed four times with 0.1 M phos- 
phoric acid. The disks were dried and radioactivity was determined by 
Cerenkov counting. 
3. RESULTS 
3.1. cdk2 transforms tau into an Alzheimer-like state 
The criteria which we have used for judging the ab- 
normal phosphorylation state of tau were developed in 
earlier studies (see [ 11,25,50]). They include a shift in the 
SDS gel in several stages, quantification of incorporated 
phosphate, sequencing of phosphopeptides, and reac- 
tion with diagnostic antibodies whose epitopes and 
phosphorylation dependence are known, and which dis- 
criminate between ormal tau and PHF-tau. These anti- 
bodies recognize SP motifs, either in the phosphorylated 
or unphosphorylated state (Fig. 1A). In addition, we 
synthesized several tau constructs, derived from the 
isoform htau23, where critical SP and TP motifs were 
mutated into AP as shown in Fig. 1B. They include the 
constructs APl 1 (all 6 SP motifs of htau23 mutated into 
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Fig. 1 (A) Bar diagram of htau40, the largest isoform of human tau in central nervous tissue, showing the location of all %-Pro and Thr-Pro motifs 
and the epitopes of several diagnostic antibodies. The numbering follows that of Goedert et al. [9]. The two hatched boxes near the N-terminus 
(29 residues each) are inserts that may be absent in smaller tau isofotms. The four boxes in the C-terminal half indicate the microtubule-binding 
repeats; repeat 2 may be absent. MAP kinase can phosphorylate all Ser-Pro or Thr-Pro motifs [8]. The main sites phosphorylated by the brain 
extract after 20 h are Sep, Ser’*, Se?, SZ?~‘, Seti%, Sep, Ser“=; Thr”‘, Th?’ (all within Ser-Pro or Thr-Pro motifs), and SerX2 and Seti” (in 
Be-Gly-Ser motifs; see [ll]). GSK3 phosphorylates preferentially the Ser-Pro motifs [26]. The diagnostic antibodies hown recognize Set--Pro motifs 
in phosphorylated or unphosphorylated form (+P or -P [2,25]). (B) Diagram of htau23 and tau constructs used in this study. From top to bottom: 
htau23 (the smallest au isoform, lacking repeat no. 2 and the two N-terminal inserts), API 1 (all six SP before and after the repeats changed into 
AP), AP17 (all 14 SP or TP motifs of htau23 changed to AP), Kl8 (the four repeats, Q244-E372, which contain no SP or TP motifs). 
AP) and AP17 (all 6 SP and 8 TP motifs mutated into 
AP, see [3]). 
The phosphorylation of tau by cdk2 is illustrated in 
Fig. 2. The M, shifts up with time in several stages, very 
similar to our earlier observations with the brain kinase 
activity, MAP kinase and GSK3 (Fig. 2,). Autoradi- 
ography (Fig. 22) shows the incorporation of phosphate 
(typically 5-6 Pi for htau23). The diagnostic antibodies 
AT8, TAU-1, SM131, SM134, and SM133 react to phos- 
phorylation similarly as with MAPK and GSK-3, indi- 
419 
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eating that SP motifs before the repeat region (S199 
and/or S202, S235) and after the repeats (S396, S404) 
become phosphorylated (Fig. 2,-2,); note that AT8, 
SMUl, and SM134 react with PHFs where the epitopes 
containing SP motifs are phosphorylated, while TAU-1 
and SM133 react with normal tau where the epitopes are 
not phosphorylated. This illustrates the characteristic 
transformation of tau into the ‘Alzheimer-like’ state. 
In spite of these similarities between MAPK, GSR3 
and cdk2, differences become apparent when one com- 
pares the tau mutants. As described earlier, MAPK 
phosphorylates essentially all SP and TP motifs while 
GSK-3 affects mainly the SP motifs. This has little effect 
on the antibody reactions (since these depend mainly on 
SP motifs; Fig. lA), but it can be seen from the total Pi 
incorporated. In the case of cdk2, we find = 5.5 Pi in 
htau23 (which contains 6 SP and 8 TP motifs), 4.5 Pi in 
API 1 (no SP, 8 TP), but only 0.6 Pi in AP17 (no SP, no 
TP), and 0.3 Pi in the repeat domain K18 (no SP, no 
TP). The comparison of total phosphate incorporated 
with the available SP or TP motifs shows that cdk2 
targets preferentially the TP motifs (i.e. the opposite of 
GSK-3), but SP motifs are also affected as shown by the 
antibody reactions. In the case of cdk5, we find = 4.2 Pi 
in htau23, otherwise its effect on SP or TP sites tends 
to be similar to that of cdk2. 
3.2. Preparation of a 31 klla tau-kinase from brain and 
iderhjication as cdk.5 
The above results demonstrated that cdk2 phos- 
phorylated tau protein at all SP motifs sensitive to 
the diagnostic antibodies, and many TP motifs as well. 
Since cdk2 is present in many tissues but not in brain 
we asked whether a similar kinase was present in brain 
cells and would qualify as a cause for abnormal phos- 
phorylation. We developed a purification scheme which 
was based on two criteria. One was the kinase activity 
towards tau protein, as judged by Pi inco~oration, gel 
shift, and reaction with the diagnostic antibodies. The 
second was the reaction with the cdc2 antibody (UBI) 
directed against the N-terminal region of cdc2 which is 
conserved in all cdk’s known so far. 
As shown in Fig. 3, several ion exchange steps fol- 
lowed by gel permeation chromato~aphy resulted in 
the purification of a single band at 31 kDa (Fig. 3A) 
which reacted with the cdc2 antibody. The kinase ac- 
tivities eluting from the ion exchange columns were high 
(up to 6 Pi incorporated into tau in 16 h). Surprisingly, 
however, the kinase activity almost disappeared uring 
gel chromato~aphy so that the highly purified kinase 
(Fig. 3A, lane 7) incorporated only < 1 Pi into tau. This 
suggested that a crucial factor was lost in the last step. 
Since most cdk’s are active only in complexes with 
their regulatory subunits (cyclins) we modifed the puri- 
fication to find the putative cofactor, using an addi- 
tional antibody specif& for the cdk variant most prom- 
inent in brain (cdk5). The first five steps of the modified 
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Fig. 2. Time course of phosphorylation of htau40 by cdk2 and im- 
munoreactivity. (1) SDS-PAGE of htau40 after incubation with the 
kinase between 0 and 24 h at 37°C. The minor lower band in lane 1 
is a fragment. Note the progressive shift to higher M, values, similar 
to the effects of brain extract and MAP kinase. (2) Autoradiography. 
(3) Immunoblot with the antibody TAUI whose reactivity is lost after 
= 2 h (following the phospho~lation of S199 and/or S202). (4) Im- 
munoblot with the PHF-specific antibody AT8 whose reactivity re- 
quires the phosphorylation of S199 and/or 5202. (5) Immunoblot with 
antibody SM134 (conformation senstive and against phosphorylated 
SP motifs before or after the repeats). (6) Blot with SMDl (epitope 
includes phosphorylated S396 and S404). (7) Blot with antibody 
SM133 which requires a dephosphorylated S235. 
procedure were the same as above, and showed that the 
31 kDa band reacted not only with the cdc2 antibody 
but also with the cdk5 antibody (Fig. 3B). After ion 
exchange chromatography on Mono-Q HR 5i5 we ob- 
served two major peaks (fraction 7-9 and 10-12, ac- 
cording to elution with -150 mM and 210 mM NaCl) 
as determined by the anti-cdk5 antibody (Fig. 3B). Al- 
though both fractions were capable of phosphorylating 
tau (not shown), the activity towards the ~34 substrate 
peptide was mainly detected in the second peak (Fig. 
3B). Applying fraction 7 of the first peak to gel filtration 
G200 Superdex yielded a fraction eluting from the col- 
umn at = 30 kDa containing a single band on SDS- 
PAGE at = 31 kDa (not shown, similar to Fig. 3A, lane 
7). However, this fraction showed only little activity in 
phosphorylating tau even after several-fold concentra- 
tion (< 1 mol Pi/m01 tau) and ~34 substrate peptide 
(c 300 cpm). 
On the other hand, fraction 10 of the second peak of 
the Mono-Q HR 5/5 when submitted to the same gel 
filtration procedure yielded several fractions that 
showed immune reactivity reactivity against cdk5 but 
not against MAP kinase or GSK-2 (Fig. 3A, lane 8) 
which eluted in the range of 50-70 kDa and showed 
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phosphorylating activity towards the p34 substrate pep- 
tide (Fig. 3C). These fractions (13-18) were pooled and 
applied onto a Mono-Q 1.6/6 Smart column (Fig. 3D, 
lane 1). The positive and active fractions eluted mainly 
in the range of 160-200 mM NaCl and were further 
purified by ion exchange chromatography on a Mono-S 
1.6/6 Smart column (Fig. 3D, lanes 2-5). This step 
yielded anti-cdk5 positive fractions eluting in the range 
of 200-220 mM NaCl. These fractions (7-9) contained 
several protein bands, including two with M, = 25 and 
31 kDa (Fig. 3D, lanes 3-5) and were capable of phos- 
phorylating htau40, incorporating 3.2, 4.2 and 2.9 mol 
Pi per mol htau40, respectively, and inducing an A4, shift 
of htau40 in SDS-PAGE. Correspondingly, these frac- 
tions show high phosphorylation activity towards the 
p34 substrate peptide. 
In conclusion, this cdcZlike kinase activity towards 
tau occurs in brain tissue and has an M, of 31 kDa. 
These features are suggestive of other cdc2-like kinases 
cloned recently from brain, termed nclk [ 141, PSSARLE 
[28], or cdk5 [42,49]. Indeed, the 3 1 kDa protein reacted 
with an antibody specific for cdk5. Thus, the kinase 
isolated here is very similar if not identical to cdk5. We 
find that this kinase shows good activity towards tau 
only when complexed with another protein of M, 
25 kDa, presumably a regulatory subunit analogous to 
one of the cyclins. The nature of this protein is not 
known at present, but its molecular weight is distinctly 
smaller than the known cyclins (as noted by Lew et al. 
~241). 
3.3. cdk5 Induces the Alzheimer-like immunoreactivity 
of tau and is bound to microtubules and PHFs 
Given the above results it remains to be shown that 
the 31 kDa kinase indeed transforms tau into the Alz- 
heimer-like state and is associated with brain microtu- 
bules. These points are illustrated in Figs. 4 and 5. The 
reaction with the diagnostic antibodies (Fig. 4) is similar 
to the examples shown previously for cdk2 (Fig. 2), 
MAP kinase [8], or GSK-3 [26], indicating the phospho- 
rylation of the SP motifs for which these antibodies are 
sensitive (serines 199, 202, 235, 396, 404; see Fig. 1). 
The association with microtubules can be shown by 
cycles of temperature-dependent microtubule assembly 
and disassembly. This is the classical method for copu- 
rifying microtubule-associated proteins, including the 
structural MAPS and microtubule-bound enzymes [46]. 
Fig. 5 shows that the 31 kDa kinase is included in the 
MAP fraction after three or more cycles of microtubule 
assembly (lanes l-6), and is also associated with PHFs 
(lane 7). In this regard, cdk5 is similar to PKA [30], 
MAP kinase, and GSK-3 [12,17,26], but distinct from 
PKC or CaMK which do not copurify with microtu- 
bules [34]. Thus, we now know three kinases, cdk5, 
MAP kinase, and GSK-3, all of which are present in 
neurons, which are capable of transforming tau into the 
Alzheimer-like state, and therefore could account for 
the pathological phosphorylation of tau in Alzheimer 
brains. 
4. DISCUSSION 
Tau protein is the major component of the paired 
helical filaments of Alzheimer’s disease. It is therefore 
of considerable interest to find out in what way the 
PHF- tau differs from normal tau. There are several 
criteria for assessing the difference. (a) PHF tau is ag- 
gregated in an abnormal fashion; this effect is probably 
based on the repeat domain of tau [47,48]. (b) PHF tau 
has an abnormally high M, due to phosphorylation 
[6,10]. An M, shift can be induced by kinases affecting 
S/T-motifs (e.g. MAP kinase, GSK-3, [8,12,17,26]), and 
in this sense the criterium of M, shift coincides with the 
criterium based on PHF-specific antibodies. However, 
an M, shift can also be induced at other sites whose 
relationship to the Alzheimer-like state is not clear (e.g. 
CaMK [1,38]; PKA, [3,36]). (c) PHFs contain full length 
tau molecules [18], but also tau abnormally cleaved 
after E391 [29]. (d) PHF tau is obviously no longer 
bound to microtubules, and it is generally thought that 
Alzheimer tau binds less tightly to microtubules (e.g. 
[5]). It has been difficult to verify this point rigorously. 
In our experience, most of the well-known kinases have 
only a weak effect on tau’s affinity for microtubules in 
vitro. Exceptions are the brain extract kinase activity 
and a 35 kDa/41 kDa kinase, both of which phospho- 
rylate S262 and thereby strongly reduce the stoichiom- 
etry [3]. This kinase has no influence on the reaction 
with PHF-specific antibodies tested so far, nor on the 
M, shift; however, it is interesting because S262 is also 
phosphorylated in PHFs [13]. (e) Finally, abnormal 
phosphorylation of tau can be detected by antibodies 
which distinguish between PHF-tau and normal tau in 
a phosphorylation-dependent manner (as in Fig. 2). The 
antibodies we have tested so far recognize SP motifs 
either in a phosphorylated or unphosphorylated state 
[2,25]. (Note that there are also PHF-specific antibodies 
that do not depend on phosphorylation but rather on 
some conformation or abnormal proteolysis, such as 
mAB Alz50 [20] or mAb 423 [29]). 
This prompted us to look for proline-directed ki- 
nases, leading the way to MAP kinase [8] and GSK-3 
[26]. MAP kinase incorporates up to 15 Pi into tau and 
phosphorylates all SP and TP motifs (17 in htau40, 14 
in htau23, see Fig. 1). GSK-3 is more restricted; both 
isoforms (a and B) incorporated up to 34 Pi, mainly at 
SP motifs. Since the diagnostic antibodies react with 
SP-containing epitopes, MAP kinase and GSK-3 gener- 
ate very similar immunoreactivities in blots. By compar- 
ison, the major phosphorylation sites we found for the 
brain extract include all SP motifs, two TP motifs, and 
the non-SP sites S262 and S356 (targets of the 35 kDa/ 
41 kDa kinase). 
One of the best known proline-directed kinase is cdc2 
421 
Volume 336, number 3 FEBSLETTERS December 1993 
which controls the celI cycle at the G2-M transition. cdc2 has relatives, the cdk family of kinases (for review 
This kinase can also affect the dynamic instability of see [28]). When we tested cdk2 it became clear that this 
microtubules, probably by phospho~lating one of the kinase was capable of phospho~lating tau in an abnor- 
MAPS (431. Although this kinase phospho~lates tau to ma1 manner at the SP motifs 199,202,235,396 and 404, 
some extent it does not induce the full PHF-like anti- judging from the Alzheimer-like antibody reaction, as 
body reaction or gel shift [8,35,45]. It seemed therefore well as many of the TP motifs. 
that this kinase was not involved in pathological phos- Nevertheless, even cdk2 seemed an unlikely candidate 
phorylation, an assumption made plausible by the fact for a pathologically active kinase since it occurs in most 
that neurons do not undergo mitosis anyway. However, tissues except in brain. We therefore looked for cdk-like 
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Fig. 4. Phosphorylation of tau by cdk5 purified from brain. This 
experiment is analogous to Fig. 2 for cdk2, but only the time points 
0 (no phosphorylation -) and 16 h (phosphorylation, +) are shown. 
PAGE, SDS-PAGE gel; AR, autoradiography, TAUl, AT-8, SM133, 
SMi31. immunoblots with antibodies. 
PHFl Blot cdk5 PHF 
ExSPS PS Tau 1 Ex S P S P S Tau 
kinases from brain (using initially the commercial cdc2 
antibody) and tested their effect on tau. This resulted in 
the purification of the 31 kDa kinase shown in Fig. 3. 
It incorporated = 4 Pi into tau, the targets were SP and 
TP motifs, and evoked the reaction with the diagnostic 
antibodies. The properties of this kinase were very sim- 
ilar or identical to the neuronal cdcZlike kinase nclk, 
also known as PSSARLE or cdk5 [14,28,42,49]. In par- 
ticular the kinase required a 25 kDa protein as cofactor 
for full activity, as described by others (e.g. [24]). The 
similarity of the kinase was confirmed by the reaction 
with an antibody specific for cdk5. 
Altogether, we have now defined four classes of ki- 
nases that are present in neurons, phosphorylate tau in 
an abnormal manner, and could thus play a role in the 
genesis of Alzheimer’s diseases. Three of these classes, 
represented by MAPK [8], GSK-3 [12,26], and cdk5 
(this report) are proline-directed kinases which phos- 
phorylate SP and/or TP motifs and induce the PHF-like 
conformation recognized by the diagnostic antibodies. 
The kinases are regulated by different phosphorylation 
cascades and respond to different extracellular signals, 
but are probably linked at common intermediate points 
(for review, see [fl). The fourth kinase (35/41 kDa) is not 
proline-directed, it phosphorylates S262 and is the only 
one that has a major effect on tart’s binding to microtu- 
bules in our hands. The interplay between the kinases 
Fig. 5. Copolymerization of cdk5 with porcine brain microtubules. (A) 
SDS gel of microtubule purification stages. Lane 1, Ex = brain 
extract = supematant after first cold spin at 4°C. Lane 2, S = superna- 
tant of first hot spin = tubulin and MAPS not assembled into microtu- 
bules after warning to 37°C; Lane 3, P = pellet of redissolved microtu- 
bules. The other lanes (46, S, P, S) show two further cycles of assem- 
bly and dissassembly by temperature shifts. Lane 7, PHF-tau prepared 
prepared according to Wischik et al. [48]. (B) Blot with anti-cdk5 
antibody, showing the 31 kDa kinase. It shows that the kinase copu- 
rifies with microtubules and is associated with PHFs. 
and the corresponding phosphatases in the genesis of 
AD remains to be established. As shown elsewhere [51], 
both calcineurin and phosphatase-2A can clear the sites 
affected by the kinases mentioned above. It may be 
significant hat the three proline-directed kinases can be 
purified as microtubule-associated proteins and are 
present in neurofibrillary tangles, suggesting that MAPS 
act as anchors for the kinases and thus are potential 
targets for them. 
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Fig. 3. Purification of cdk5 from brain. (A) Left panel: SDS-PAGE after Coomassie blue staining (lane 16) or silver staining (lanes 7,8). Lane 
M, molecular weight standards as indicated, (lane 1) crude brain extract; (lane 2) flow-through fraction of Q-Sepharose ion exchange chromatog- 
raphy; (lane 3) pool of fractions of S-Sepharose ion exchange chromatography; (lane 4) pool of fractions of SP-Sepharose HP ion exchange 
chromatography; (lane 5) pool of fractions of Mono-Q HR lO/lO ion exchange chromatography; (lane 6) pool of fractions after Mono-Q HR 5/5 
ion exchange chromatography; (lane 7) fraction 24 of G-200 gel filtration, showing a single band at 31 kDa; (lane 8) pool of fractions 13-18 of 
G-200 Superdex gel filtration. Right panel: immtmoblot with anti-cdk5 antibody, lanes l-8 show the same samples as seen on the left panel. (B) 
Anion exchange chromatography by Mono Q HR 5/5. Upper panel, fractions 7-12 were screened for phosphorylation of p34 substrate peptide. 
Lower panel, immunoblot with anti-cdk5 antibody of the same fractions as seen above. Note that the cdk5 elutes in two maxima as determined 
by the specific antibody, but only the right peak (fraction 10-12) has high activity for phosphorylating the peptide substrate, whereas the left peak 
(fraction 7-8) has low activity. (C) Gel filtration (Superdex G-200) of fraction 10 obtained after Mono-Q HR 5/5 ion exchange chromatography. 
Upper panel, plot of phosphorylation activity for p34 substrate peptide of every second fraction (triangles). Lower panel, immunoblot of the same 
fractions as seen above. Note that the highest phosphorylation activity coincides with the presence of cdk5 as indicated by immunoblot and 
corresponds to a molecular weight of ca. 5&70 kDa (see calibration line with marker proteins, squares). (D) Final purification of active brain cdk5. 
SDS-PAGE after silver staining. Lane 1, pool of fractions 1318 obtained after G-200 Superdex gel filtration; lane 2, pool of fractions 5-7 of 
Mono-Q 1.6/6 Smart ion exchange chromatography; lanes 3-5, fractions 7, 8 and 9 of Mono-S 1.6/6 Smart ion exchange chromatography. 
Lane M, molecular weight standards as indicated. 
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